Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Cancers
|
June 13, 2025
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data
Sara Stumpo, Andrea Carlini, Francesco Mantuano, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 1, 2026
Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized Care
Claudia Parisi, Andrea De Giglio, Marco Banini, et al.
JTO Clinical and Research Reports
|
April 20, 2026
Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced <i>EGFR</i>-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data
Alessandro Di Federico, Sara Stumpo, Linda Danielli, et al.
The Lancet. Oncology
|
October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
JAMA Oncology
|
June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis
Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Federica Pecci, Hui Li, Alessandro Di Federico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib
Alessandro Di Federico, Federica Pecci, Mark Jeng, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Cancers
|
June 13, 2025
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data
Sara Stumpo, Andrea Carlini, Francesco Mantuano, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 1, 2026
Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized Care
Claudia Parisi, Andrea De Giglio, Marco Banini, et al.
JTO Clinical and Research Reports
|
April 20, 2026
Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced <i>EGFR</i>-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data
Alessandro Di Federico, Sara Stumpo, Linda Danielli, et al.
The Lancet. Oncology
|
October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
JAMA Oncology
|
June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis
Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Federica Pecci, Hui Li, Alessandro Di Federico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib
Alessandro Di Federico, Federica Pecci, Mark Jeng, et al.
Page
of 1